Location of Repository

Exploring the Structure, Function & Regulation of the Human Glucagon-Like Peptide-1 Receptor

By Yan Huang


Glucagon-like peptide-1 (GLP-1) enhances glucose-dependent insulin secretion and promotes β-cell function via its receptor (GLP-1R), which therefore is a validated target for the treatment of type 2 diabetes. Due to difficulties with peptide therapeutics, it is important to find small-molecule GLP-1R agonists. This leads to a need to understand the structure, function and regulation of the receptor, particularly, differences between agonisms mediated by GLP-1 (orthosteric agonist) and small molecules. \ud The GLP-1R contains a putative N-terminal signal peptide sequence, which is assessed here by recombinantly expressing several epitope-tagged GLP-1R constructs in HEK293 cells. The findings demonstrate that the GLP-1R is expressed predominately at the plasma membrane and also slightly cytosolic. Only fully glycosylated, mature form of the receptor is able to traffic to the cell surface and performs the function. The signal peptide sequence of the GLP-1R is essential for synthesis. After fulfilling the function, this sequence is cleaved and thus not part of the mature protein. The cleavage of signal peptide is critical for processing and trafficking of the GLP-1R. Based on one of these constructs generated here, a cell line (HEK293: GLP-1R-EGFP) with stable expression of the visible GLP-1R is established, which allows observations and determinations for ligand-mediated receptor internalisation in real time. \ud Compound 2 (6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline) has been described as a GLP-1R allosteric modulator and agonist. Findings here that compound 2-mediated agonisms on both the wild-type (WT) GLP-1R and the mutant with removal of the N-terminal domain provide direct evidence for the allosteric agonism. Interestingly, compound 2-mediated cAMP response is enhanced by orthosteric antagonist exendin 9-39, but the latter inhibits receptor internalisation mediated by compound 2. \ud Recently, it has been hypothesised that the binding of GLP-1 allows a sequence of NRTFD (Asn63-Asp67) in the N-terminus of the GLP-1R to interact with another part of the receptor and cause agonism. This was examined here by generating receptor mutants and synthetic peptides. Findings here that Asp67 plays a key role in stabilising the N-terminal structure of the GLP-1R and thus is critical for processing and trafficking of the receptor protein do not support such hypothesis although synthetic NRTFD mediates a weak and partial agonism on the WTGLP-1R

Publisher: University of Leicester
Year: 2011
OAI identifier: oai:lra.le.ac.uk:2381/8969

Suggested articles



  1. (2010). 3. [Epub ahead of print] Ashby MC, Ibaraki K and Henley JM
  2. (2009). 7TM receptor allostery: putting numbers to shapeshiftinG-proteins. Trends Pharmacol Sci.
  3. (2009). A comprehensive assessment of Nterminal signal peptides prediction methods.
  4. (2005). A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept.
  5. (1993). A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model.
  6. (1997). A neural network method for identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites.
  7. A prospective cohort study of men in the normative aging study.
  8. (2009). A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther.
  9. (2009). A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug Des Devel Ther.
  10. (2009). A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism.
  11. (1999). A Short Lived Protein Involved in the Heat Shock Sensing Mechanism Responsible for Stress-activated Protein Kinase 2 (SAPK2/p38) Activation.
  12. (1999). A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis.
  13. (2009). A signal-anchor sequence stimulates signal recognition particle binding to ribosomes from inside the exit tunnel.
  14. (1971). A simple and sensitive saturation assay method for the measuremant of adenosine 3959-cyclic monophosphate.
  15. (2005). A substrate-specific inhibitor of protein translocation into the endoplasmic reticulum
  16. (2008). Adolphe Quetelet (1796-1874)—the average man and indices of obesity.
  17. (2004). Advances in the prediction of protein targeting signals.
  18. (2006). Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors.
  19. (1995). Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas.
  20. (2009). Akt and PTEN: beta-cell mass and pancreas plasticity. Trends Endocrinol Metab.
  21. (2009). alanine substitution mutations, Val also interacts with Val and other residues e.g. Arg and Arg
  22. (2007). Allosteric enhancers, allosteric agonists and agoallosteric modulators: where do they bind and how do they act? Trends Pharmacol Sci.
  23. (2010). Allosteric ligands for G-protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. Med Res Rev.
  24. (2009). Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders. Pharmacol Exp Ther.
  25. (2003). Allosteric modulators of G-protein-coupled receptors.
  26. (2010). American Council on Exercise BMI Calculator at Ace Fitness: http://www.acefitness.org/calculators/bmi-calculator.aspx, accessed 07
  27. (2007). amino or carboxyl terminus.
  28. (1987). An analysis of 59-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res.
  29. (2009). An efficient platform for screening expression and crystallization of glycoproteins produced in human cells.
  30. (2008). An escort for GPCRs: implications for regulation of receptor density at the cell surface. Trends Pharmacol Sci.
  31. and Alvarez E (2005b) Substitution of the cysteine 438 residue in the cytoplasmic tail of the glucagon-like peptide-1 receptor alters signal transduction activity.
  32. (2010). and Ulloa-Aguirre A
  33. (2007). Anti-diabetes and anti-obesity medications: effects on weight in people with diabetes. Diabetes Spectr.
  34. (2009). Architecture, function and prediction of long signal peptides.
  35. (2008). BacMam system for high-level expression of recombinant soluble and membrane glycoproteins for structural studies. Protein Expr Purif.
  36. (2009). Balancing risk and benefit with oral hypoglycemic drugs.
  37. (2009). Bavec A and Licar A
  38. (1991). Beta-adrenoceptor-agonist and insulin actions on glucose metabolism in rat skeletal muscle in different thyroid states.
  39. (2007). Beta-arrestins and cell signaling. Annu Rev Physiol.
  40. (2006). Biochem Comparative analysis of the human angiotensin II type 1a receptor heterologously produced in insect cells and mammalian cells.
  41. (2010). Biochem N-Glycosylation plays a role in protein folding of human UGT1A9.
  42. (1993). Biological effects and metabolic rates of glucagon-like peptide-1(7–36) amide and glucagon-like peptide-1(7–37) in healthy subjects are indistinguishable. Diabetes 42:658–661.
  43. Blazquez E and Alvarez E (2005a) The cytoplasmic domain close to the transmembrane region of the glucagon-like peptide-1 receptor contains sequence elements that regulate agonist-dependent internalisation.
  44. (2008). Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice. PLoS One.
  45. (2004). Brubaker PL.Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells.
  46. (2009). Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.
  47. (1970). Calcium-dependent bacteriophage DNA infection.
  48. (2003). cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2.
  49. (2000). cAMP-GEFII is a direct target of cAMP in regulated exocytosis.
  50. (2003). Cationic trypsinogen and pancreatic secretory trypsin inhibitor gene mutations in neonatal hypertrypsinaemia.
  51. (1998). Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane.
  52. (2002). Cell biology. A last GASP for GPCRs?
  53. (2000). Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion.
  54. (2000). Characterization of glucagon-like peptide-1 receptor-binding determinants.
  55. (2007). Chemical chaperone and inhibitor discovery: potential treatments for protein conformational diseases. Perspect Medicin Chem.
  56. (2006). Class B GPCRs: a hidden agonist within? Mol Pharmacol.
  57. (1997). Classification of diabetes on the basis of etiologies versus degree of insulin deficiency.
  58. (2007). Clathrin-dependent mechanisms of G-protein-coupled receptor endocytosis.
  59. (2008). Clathrin-independent endocytosis: from nonexisting to an extreme degree of complexity.
  60. (2009). Clinical Guidelines Technical Team
  61. (1993). Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor.
  62. (2006). Co- and post-translational translocation through the protein conducting channel.
  63. (2010). Comparative Effects of the Endogenous Agonist GLP-1 7-36 Amide and a Small Molecule Ago-allosteric Agent 'Compound 2' at the GLP-1 Receptor.
  64. (1989). Complete sequences of glucagon-like peptide-1 from human and pig small intestine.
  65. (1976). Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus.
  66. (2001). Critical role of cAMP-GEFII–Rim2 complex in incretin potentiated insulin secretion.
  67. (2010). Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor.
  68. (2000). Crystal structure of rhodopsin: a G-protein-coupled receptor.
  69. (2008). Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain.
  70. (2009). Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.
  71. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet.
  72. (2002). Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
  73. (2009). Delivering proteins for export from the cytosol. Nat Rev Mol Cell Biol.
  74. (2002). Demonstration of reduced in vivo surface expression of activating mutant thyrotrophin receptors in thyroid sections.
  75. (1996). Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate. Mol Endocrinol.
  76. (2009). Determination of glycosylation sites and site-specific heterogeneity in glycoproteins.
  77. (2010). Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. Diabetes Obes Metab.
  78. (2009). Diabetic patients: epidemiology and global impact.
  79. (2009). Dietary fats and prevention of type 2 diabetes.
  80. (2001). Different domains in the third intracellular loop of the GLP-1 receptor are responsible for G s and G i/G o activation. Biochim Biophys Acta Protein Struct Mol Enzymol
  81. (2003). Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling.
  82. (2006). Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
  83. (1998). Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extendedmetabolic stability and improved biological activity. Diabetologia 41:271–278.
  84. (2009). Discovery of new GPCR biology: one receptor structure at a time.
  85. (2009). Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2.FEBS
  86. (2009). Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. Diabetes Res Clin Pract.
  87. (2010). Dritselis A and Kirkpatrick P
  88. (2009). Early insulin treatment in type 2 diabetes: what are the cons? Diabetes Care.
  89. (2009). Early insulin treatment in type 2 diabetes: what are the pros? Diabetes Care.
  90. (2002). Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity and beta-cell function in type 2 diabetes: a parallel-group study.
  91. (2009). Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
  92. (2006). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
  93. (2004). Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
  94. (2009). Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. Med Chem.
  95. (2009). Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
  96. Endocrinology 140:5102-5111 Pantazaka E and Taylor CW (2009). Targeting of inositol 1,4,5-trisphosphate receptor to the endoplasmic reticulum by its first transmembrane domain.
  97. (2009). Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling.
  98. (2009). Enhancement of the surface expression of G proteincoupled receptors. Trends Biotechnol.
  99. (2010). Environmental transition of signal-anchor sequences during membrane insertion via the endoplasmic reticulum translocon.
  100. (2003). Epac: a new cAMP target and new avenues in cAMP research.
  101. (2004). Epac: A new cAMP-bindinG-protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell.
  102. (2009). ER and aging-Protein folding and the ER stress response. Ageing Res Rev.
  103. (2009). Essentials of Glycobiology. 2nd edition.
  104. (2005). Evaluating eukaryotic secreted protein prediction.
  105. (2009). Evaluation of signal peptide prediction algorithms for identification of mycobacterial signal peptides using sequence data from proteomic methods.
  106. (2003). Evolution of Trypsinogen Activation Peptides.
  107. (2001). Evolving concepts in G-protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev.
  108. (2009). Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver.
  109. (1993). Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
  110. (2003). Expression of EGFP-amino-tagged human mu opioid receptor in Drosophila Schneider 2 cells: a potential expression system for large-scale production of Gprotein coupled receptors. Protein Expr Purif.
  111. (2006). Expression of human cationic trypsinogen with an authentic N terminus using intein-mediated splicing in aminopeptidase P deficient Escherichia coli. Protein Expr Purif.
  112. (1993). Expression of soluble recombinant glycoproteins with predefined glycosylation: application to the crystallization of the T-cell glycoprotein CD2. Protein Eng.
  113. (2008). Expression of the GLP-1 receptor in mouse, rat, and human pancreas.
  114. (2005). Families of membranous proteins can be characterized by the amino acid composition of the thransmembrane domains Bioinformatics.
  115. (2001). Family-B G-protein-coupled receptors. Genome Biol.
  116. (2009). Fate of the beta-cell in the pathophysiology of type 2 diabetes.
  117. (2009). Fine-tuning of GPCR activity by receptor-interacting proteins.
  118. (1997). Five Out of Six Tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1.
  119. (2008). Flanking signal and mature peptide residues influence signal peptide cleavage. BMC Bioinformatics.
  120. (1997). FluoresceinTrp25-exendin-4, a biologically active fluorescent probe for the human GLP-1 receptor.
  121. (2009). Folding scene investigation: membrane proteins.
  122. (2007). Functional consequences of alteration of N-linked glycosylation sites on the neurokinin 1 receptor
  123. (2007). Functional selectivity and classical concepts of quantitative pharmacology. Pharmacol Exp Ther.
  124. (2007). G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacol Rev.
  125. (2010). G protein-coupled receptors: the inside story.
  126. (2008). G-protein-coupled receptor phosphorylation: where, when and by whom.
  127. (2008). G-protein-coupled receptor sorting to endosomes and lysosomes. Annu Rev Pharmacol Toxicol.
  128. (2009). G-protein-coupled receptorfocused drug discovery using a target class platform approach. Drug Discov Today.
  129. (2008). G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms.
  130. (1996). Gastric emptying and release of incretin hormones after glucose ingestion in humans,
  131. (2007). Generation and functional characterization of fluorescent, N-terminally tagged CB1 receptor chimeras for live-cell imaging. Mol Cell Neurosci.
  132. (2004). Generation and Use of Epitope-Tagged Receptors.Willars GB and
  133. (2009). Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia.
  134. (2001). Global and societal implications of the diabetes epidemic.
  135. (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract.
  136. (2006). GLP-1 and type 2 diabetes: physiology and new clinical advances. Curr Opin Pharmacol.
  137. (2010). GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. Cell Metab.
  138. (2010). GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells.
  139. (2010). Glucagon and glucagon-like peptides 1 and 2. Results Probl Cell Differ.
  140. (2003). Glucagon like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′AMP dependent protein kinase Aand a PI3K-dependent pathway,
  141. (2007). Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept.
  142. (2007). Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.
  143. (1987). Glucagon-like peptide-1 7-36: a physiological incretin in man.
  144. (2009). Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of
  145. (2004). Glucagon-like peptide-1 prevents β-cell glucolipotoxicity.
  146. (2005). Glucagon-like peptide-1 protects β-cells from cytokine-induced apoptosis and necrosis: role of protein kinase B.
  147. (2010). Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.
  148. (1996). Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor.
  149. (1986). Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas.
  150. (2010). Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. Diabetes Obes Metab.
  151. (2007). Glycoprotein Structural Genomics: Solving the Glycosylation Problem.
  152. (1999). Glycosylation is important for binding to human calcitonin receptors.
  153. (2004). Glycosylation is important for cell surface expression of the water channel aquaporin-2 but is not essential for tetramerization in the endoplasmic reticulum.
  154. (2001). Glycosylation of human CRLR at Asn123 is required for ligand binding and signalling.
  155. (2000). Glycosylation of the calcitonin receptor-like receptor at Asn60 or Asn112 is important for cell surface expression.
  156. (1994). Glycosylation of the GLP-1 receptor is a prerequisite for regular receptor function.
  157. (1987). Glycosylation of the mammalian α1-adrenergic receptor by complex type N-linked oligosaccharides.
  158. (2009). GPCR and G-proteins: drug efficacy and activation in live cells.
  159. (2001). Helenius A
  160. (2004). Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.
  161. (2001). How membranes shape protein structure.
  162. (2006). http://www.staff.ncl.ac.uk/philip.home/who_dmc.htm World Health Organization
  163. (2006). Human bradykinin B2 receptor sialylation and N-glycosylation participate with disulfide bonding in surface receptor dimerization.
  164. (1994). Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Biophys Res Commun.
  165. (2006). Hyperglycemic crises in diabetes mellitus: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Endocrinol Metab Clin North Am.
  166. (2005). Hyperosmolar hyperglycemic state.
  167. (2009). Identification of cAMP-dependent kinase as a third in vivo ribosomal protein S6 kinase in pancreatic beta-cells.
  168. (1995). Identification of N-glycosylation sites in the gonadotropinreleasing hormone receptor: role in receptor expression but not ligand binding.
  169. (2010). Identification of potent 11mer glucagon-like peptide-1 receptor agonist peptides with novel C-terminal amino acids: Homohomophenylalanine analogs.
  170. (1997). Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites.
  171. (2000). Identification of the sites of asparagine-linked glycosylation on the human thyrotropin receptor and studies on their role in receptor function and expression.
  172. (1995). Identification of the sites of N-linked glycosylation on the follicle-stimulating hormone (FSH) receptor and assessment of their role in FSH receptor function.
  173. (2009). Illuminating the life of GPCRs.
  174. (2010). Importance of extracellular loop one of the neuropeptide S receptor for biogenesis and function.
  175. (2005). Importance of N-glycosylation positioning for cell-surface expression, targeting, affinity and quality control of the human AT1 receptor.
  176. (2003). Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies.
  177. (2006). Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1).
  178. (2002). In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor. Biophys Chem.
  179. (1986). Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.
  180. (2007). Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism.
  181. (2008). Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs.
  182. (2010). Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care.
  183. (1987). Inhibitors of the biosynthesis and processing of N-linked ligosaccharide chains. Annu Rev Biochem.56:497-534.
  184. (2006). Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes.
  185. (2008). Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. Mol Endocrinol.
  186. (2005). Insights into the structure and molecular basis of ligand docking to the g protein-coupled secretin receptor using charge-modified amino-terminal agonist probes. Mol Endocrinol
  187. (2009). Insulin therapy for type 2 diabetes. Diabetes Care.
  188. (2010). Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab.
  189. (2010). Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
  190. (2007). Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism.
  191. (1989). Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.
  192. (1997). Internalization and homologous desensitization of the GLP-1 receptor depend on phosphorylation of the receptor carboxyl tail at the same three sites.
  193. (2009). Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
  194. (2001). Intracellular functions of N-linked glycans.
  195. (2002). Intracellular trafficking of a tagged and functional mammalian olfactory receptor.
  196. (2004). Intranasal insulin improves memory in humans.
  197. (1996). Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors.
  198. (2006). Islet β-cell failure in type 2 diabetes.
  199. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas,
  200. (1991). Kex2-like endoproteases PC2 and PC3 accurately cleave a model prohormone in mammalian cells: evidence for a common core of neuroendocrine processing enzymes.
  201. (2006). L25 functions as a conserved ribosomal docking site shared by nascent chain-associated complex EMBO Rep.
  202. (2010). Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives. Patient Prefer Adherence.
  203. (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
  204. (2008). Mammalian Rho GTPases: new insights into their functions from in vivo studies.
  205. (2009). Mapping the human membrane proteome: a majority of the human membrane proteins can be classified according to function and evolutionary origin.
  206. (1986). Mechanism of protein translocation across the endoplasmic reticulum membrane.
  207. (2002). Mechanisms of cross-talk between G-protein-coupled receptors.
  208. (2008). Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol.
  209. (2009). Mechanisms of endocytosis.
  210. (2005). Mechanisms of peptide and nonpeptide ligand binding to Class B Gprotein-coupled receptors. Drug Discov. Today 10:417–427.
  211. (2008). mechanisms of protein transport to the cell surface of eukaryotic cells. Annu Rev Cell Dev Biol.
  212. (2009). Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab.
  213. (2009). Melanocortin 5 receptor activates ERK1/2 through a PI3K-regulated signaling mechanism. Mol Cell Endocrinol.
  214. (2004). Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues.
  215. (2009). Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes.
  216. (2001). Molecular Cloning: A Laboratory Manual, 3rd edition,
  217. (2002). Molecular insights into insulin action and secretion
  218. (2010). Molecular insights into mechanisms of intramembrane proteolysis through signal peptide peptidase (SPP).
  219. (2009). Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: the GnRH receptor. Mol Endocrinol.
  220. (2004). Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther.
  221. (2010). Molecular mechanisms underlying nutrient detection by incretinsecreting cells.
  222. (2009). Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists.
  223. (1999). Molecular tinkering of G protein-coupled receptors: an evolutionary success.
  224. (2009). mu-Opioid receptor cell surface expression is regulated by its direct interaction with Ribophorin I. Mol Pharmacol.
  225. (2009). Multiple conformational switches in a GTPase complex control co-translational protein targeting.
  226. (2010). Mutant proinsulin proteins associated with neonatal diabetes are retained in the endoplasmic reticulum and not efficiently secreted.
  227. (1990). Mutational analysis of beta-adrenergic receptor glycosylation.
  228. (1999). Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells.
  229. (2001). N-glycosylation of CRF receptor type 1 is important for its ligand-specific interaction.
  230. (1985). New developments in the incretin concept.
  231. (1999). Nglycosylation requirements for the AT1a angiotensin II receptor delivery to the plasma membrane.
  232. (1993). Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
  233. (1992). Obesity and body fat distribution in relation to the incidence of non-insulin-dependent diabetes mellitus.
  234. (2008). Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
  235. (2009). Overview of insulin replacement therapy.
  236. (2007). Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s). J Pharmacol Exp Ther.
  237. (1987). Pancreatic and intestinal processing of proglucagon in man.
  238. (1999). Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells.
  239. (2005). Pathogenesis of type 2 diabetes mellitus. Arch Med Res.
  240. (2007). Pathways of clathrin-independent endocytosis,
  241. (2007). Peptide binding at the GLP-1 receptor. Biochem Soc Trans.
  242. (2010). Peptide drugs to target G proteincoupled receptors. Trends Pharmacol Sci.
  243. (2009). Persistent cAMP-signals triggered by internalized G-proteincoupled receptors.
  244. (2010). Pharmacological characterization of human incretin receptor J Pharmacol Exp Ther.
  245. (2009). Physical inactivity and obesity: links with insulin resistance and type 2 diabetes mellitus. Diabetes Metab Res Rev.
  246. (2008). Physiological roles of ribosomal protein S6: one of its kind.
  247. (2008). PKR regulates B56α-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells.
  248. (1967). Plasma Insulin Responses to Oral and Intravenous Glucose – Studies in Normal and Diabetic Subjects.
  249. (2008). Plasmids: Current Research and Future Trends. Caister Academic Press.
  250. (1996). Point mutation in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling.
  251. (2006). Possible endogenous agonist mechanism for the activation of secretin family G protein- coupled receptors. Mol Pharmacol.
  252. (1998). Prediction of signal peptides and signal anchors by a hidden Markov model.
  253. (2008). Prediction of signal peptides in protein sequences by neural networks.
  254. (1986). Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing.
  255. (1993). Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
  256. (2005). Prevention of type 2 diabetes by diet and lifestyle modification.
  257. (1999). Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1).
  258. (1994). Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells.
  259. (1995). Properties of N-terminal tails in G-protein coupled receptors: a statistical study.
  260. (2009). Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol.
  261. (2009). Protein targeting by the signal recognition particle.
  262. (2007). Protein translocation: checkpoint role for SRP GTPase activation.
  263. (2002). Purification and characterization of a receptor for human parathyroid hormone and parathyroid hormone-related peptide.
  264. (1989). Quantitative evaluation of Escherichia coli host strains for tolerance to cytosine methylation in plasmid and phage recombinants. Nucleic Acids Res.
  265. (2007). Quantitative trait loci for carbohydrate and total energy intake on mouse chromosome 17: congenic strain confirmation and candidate gene analyses
  266. (2001). Rapid down-regulation of the type I inositol 1,4,5-trisphosphate receptor and desensitization of gonadotropin-releasing hormone-mediated Ca2+ responses in alpha T3-1 gonadotropes.
  267. (2007). RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation.
  268. (2003). Receptor Signal Transduction Protocols. Second edition.
  269. (2010). Recognition of a signal peptide by the signal recognition particle.
  270. (2005). Recognition of transmembrane helices by the endoplasmic reticulum translocon.
  271. (2008). Reduced incretin effect in obese subject with normal glucose tolerance as compared to lean control subjects,
  272. (1997). Reducing cellular autofluorescence in flow cytometry: an in situ method.
  273. (1995). Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9–39) amide.
  274. (2007). Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol.
  275. (2001). Relationships of upper gastrointestinal motor and sensory function with glycemic control.
  276. (2002). Requirements for signal peptide peptidasecatalyzed intramembrane proteolysis. Mol Cell.
  277. (2005). Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev.
  278. (2009). Ribosomal S6 kinase 2 directly phosphorylates the 5-hydroxytryptamine 2A (5-HT2A) serotonin receptor, thereby modulating 5-HT2A signalling.
  279. (2010). Role of Asparagine-Linked Glycosylation
  280. (2000). Role of asparagine-linked oligosaccharides in the function of the rat PTH/PTHrP receptor.
  281. (2006). Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus.
  282. (1981). Role of glycosylation and protein synthesis in insulin receptor metabolism by 3T3-L1 mouse adipocytes.
  283. (1996). Role of glycosylation in expression and function of the human parathyroid hormone/parathyroid hormone-related protein receptor.
  284. (2004). Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.
  285. (2010). Role of N-linked glycosylation in biosynthesis, trafficking, and function of the human glucagon-like peptide 1 receptor.
  286. (1999). Role of N-linked glycosylation on the function and expression of the human secretin receptor.
  287. (2010). Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebocontrolled study. Diabet Med.
  288. (2007). Sarrafzadegan N and Tchernof A
  289. (1997). Scanning of the glucagon-like peptide-1 receptor localizes G-protein-activating determinants primarily to the N terminus of the third intracellular loop.
  290. (2004). Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
  291. (2000). Secretory protein trafficking and organelle dynamics in living cells. Annu Rev Cell Dev Biol.16:557-589.
  292. (2010). Sedo A
  293. (1979). Selective cytotoxicity of tunicamycin for transformed cells.
  294. (2009). Sequencespecific retention and regulated integration of a nascent membrane protein by the endoplasmic reticulum Sec61 translocon.
  295. (2005). Sequential triage of transmembranesegments by Sec61alpha during biogenesis of a native multispanning membrane protein.
  296. (2010). Seven transmembrane receptors as shapeshiftinGproteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev.
  297. (2009). Signal anchor sequence provides motive force for polypeptide chain translocation through the endoplasmic reticulum membrane.
  298. (2010). Signal peptide peptidase (SPP) assembles with substrates and misfolded membrane proteins into distinct oligomeric complexes.
  299. (2009). Signal peptide peptidases: a family of intramembrane-cleaving proteases that cleave type 2 transmembrane proteins. Semin Cell Dev Biol.
  300. (2004). Signal peptide prediction based on analysis of experimentally verified cleavage sites.
  301. (2003). Signal sequence cleavage and plasma membrane targeting of the retinal rod NCKX1 and cone NCKX2 Na+/Ca2+ - K+ exchangers.
  302. (2008). Signal sequenceindependent membrane targeting of ribosomes containing short nascent peptides within the exit tunnel.
  303. (1996). Signal transduction and desensitization of the glucagon-like peptide-1 receptor.
  304. (1994). Signal transduction of the GLP-1-receptor cloned from a human insulinoma.
  305. (2010). Signaling by internalized Gprotein-coupled receptors. Trends Pharmacol Sci.
  306. (2009). Signaling through G-protein coupled receptors.
  307. (2004). Single-cell imaging of intracellular Ca2+ and phospholipase C activity reveals that
  308. (1990). Site-directed mutagenesis of the m2 muscarinic acetylcholine receptor. Analysis of the role of N-glycosylation in receptor expression and function.
  309. Small-molecule agonists for the glucagon-like peptide 1 receptor.
  310. (1992). Solubilization of active GLP-1 (7-36) amide receptors from RINm5F plasma membranes.
  311. (2009). Strategies for analysis of the glycosylation of proteins: current status and future perspectives.
  312. (1995). Structural and functional analysis of the canine histamine H2 receptor by site-directed mutagenesis: N-glycosylation is not vital for its action.
  313. (2010). Structural determinants underlying constitutive dimerization of unoccupied human follitropin receptors. Cell Signal.
  314. (1968). Structure of hemoglobin A1c: nature of the Nterminal beta chain blocking group.
  315. (2004). Structure of the signal recognition particle interacting with the elongationarrested ribosome.
  316. (2002). Structure-function of the glucagon receptor family of G-protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels 8:179–188.
  317. (2007). Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Curr Drug Targets.
  318. (1969). Studies of an unusual hemoglobin in patients with diabetes mellitus.
  319. (2009). Sustained cyclic AMP production by parathyroid hormone receptor endocytosis.
  320. (2005). Targeting proteins to membranes: structure of the signal recognition particle. Curr Opin Struct Biol.15:
  321. (2007). Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy Nat Rev Microbiol.
  322. (2006). The 7 TM G-protein-coupled receptor target family.
  323. (2008). The concept of translocational regulation.
  324. (2006). The corticotropin-releasing factor receptor type 2a contains an N-terminal pseudo signal peptide.
  325. (2010). The dipeptidyl peptidase IV family in cancer and cell biology.
  326. (1999). The dolichol pathway of N-linked glycosylation.
  327. (2010). The early endosome: a busy sorting station for proteins at the crossroads. Histol Histopathol.
  328. (2009). The effects of GLP-1 infusion in the hepatic portal region on food intake. Regul Pept.
  329. (2010). The evolving place of incretin-based therapies in type 2 diabetes.
  330. (1997). The hydrophobic region of signal peptides is a determinant for SRP recognition and protein translocation across the ER membrane.
  331. (2009). The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol.
  332. (2003). The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
  333. (2007). The Low-Density Lipoprotein Class A Module of the Relaxin Receptor (Leucine-Rich Repeat Containing GProtein Coupled Receptor 7): Its Role in Signaling and Trafficking to the Cell Membrane Endocrinology
  334. (2007). The Metabolic Syndrome - a global challenge for prevention. Horm Metab Res.
  335. (1974). The nature and metabolism of the carbohydrate-peptide linkages of glycoproteins.
  336. (2007). The physiology of glucagon-like peptide 1,
  337. (2007). The Physiology of Glucagon-like Peptide 1.
  338. (2003). The positive charge at Lys-288 of the glucagon-like peptide-1 (GLP-1) receptor is important for binding the N-terminus of peptide agonists.
  339. (2010). The pseudo signal peptide of the corticotropin-releasing factor receptor type 2a decreases receptor expression and prevents Gi-mediated inhibition of adenylyl cyclase activity.
  340. (2005). The regulatory mechanisms of export trafficking of G protein-coupled receptors. Cell Signal.
  341. (2009). The ribosome as a platform for co-translational processing, folding and targeting of newly synthesized proteins.
  342. (2009). The sequence after the signal peptide of the G protein-coupled endothelin B receptor is required for efficient translocon gating at the endoplasmic reticulum membrane. Mol Pharmacol.
  343. (2005). The signal peptide of the rat corticotropin-releasing factor receptor 1 promotes receptor expression but is not essential for establishing a functional receptor.
  344. (1990). The signal peptide.
  345. (2005). The signal recognition particle and its interactions during protein targeting.
  346. (2006). The structure of the Sec complex and the problem of protein translocation.
  347. (2006). The surprising complexity of signal sequences. Trends Biochem Sci.
  348. (1996). The third cytoplasmic domain of the tGLP-1 (7–36 amide) receptor is required for coupling to the adenylyl cyclase system.
  349. (2010). The year in G-protein-coupled receptor research. Mol Endocrinol.
  350. (1996). Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide 1 receptor.
  351. (1995). Tissue-specific expression of the human receptor for glucagon-like peptide 1: brain, heart and pancreatic forms have the same deduced amino acid sequences.
  352. (2008). Topology of molecular machines of the endoplasmic reticulum: a complilation of proteomics and cytological data. Histochem Cell Biol.
  353. (2009). Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease. Mol Cell Endocrinol.
  354. (2010). Trafficking and signalling of gonadotrophin-releasing hormone receptors: an automated imaging approach.
  355. (2000). Translational regulation of proinsulin biosynthesis and proinsulin conversion in the pancreatic beta-cell. Semin Cell Dev Biol.
  356. (2005). Transmembrane helices before, during, and after insertion. Curr Opin Struct Biol.
  357. (2009). Transplantation of PC1/3-Expressing α-cells Improves Glucose Handling and Cold Tolerance in Leptin-resistant Mice. Mol Ther.
  358. Twenty-four hour profiles of insulin, substrates and gut incretin hormones: early defects in glucose tolerant offspring of type II (non-insulin dependent) diabetic patients. Diabetologia 42:1314–1323.
  359. (2008). Type 1 diabetes mellitus in pediatrics. Pediatr Rev. 29(11)374-384; quiz 385.
  360. (2010). Type 2 diabetes: an expanded view of pathophysiology and therapy. Postgrad Med.
  361. (2008). Use of synthetic signal sequences to explore the protein export machinery.
  362. (2010). Using automated imaging to interrogate gonadotrophin-releasing hormone receptor trafficking and function.
  363. (2000). Using green fluorescent proteins to study G-protein– coupled receptor localization and trafficking. Trends Pharmacol.
  364. (2009). Vegetarian and vegan diets in type 2 diabetes management. Nutr Rev.
  365. (2009). Visualization of distinct entities of the SecYEG translocon during translocation and integration of bacterial proteins.
  366. (2010). Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care.
  367. (2010). What is diabetes? Available at http://www.diabetes.org.uk/Guide-todiabetes/Introduction-to-diabetes (accessed on 18
  368. (1999). World Health Organization
  369. (1987). XL1-Blue: a high efficiency plasmid transforming recA Escherichia coli strain with beta-galactosidase selection.
  370. Zhang L and Bisello A (2006) Caveolin-1 regulates cellular trafficking and function of the glucagon-like peptide 1 receptor. Mol Endocrinol 20:3400–3411.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.